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The SR-domain protein kinase (SRPK) 1 and 2 are two important kinases involved in cellular RNA splicing. Recently, it was suggested
that these two kinases, which could bind to the hepatitis B virus (HBV) core protein, might be the major cellular kinases that phosphorylate
the core protein to regulate HBV replication. In this report, we tested the role of SRPK1 and SRPK2 in HBV replication and found that both
of them could suppress HBV replication by reducing the packaging efficiency of the pgRNAwithout affecting the formation of the viral core
particles. This suppressive effect of SRPK1 and SRPK2 on HBV replication cannot be explained by their phosphorylation activities on the
HBV core protein as the over-expression of these two kinases had no detectable effects on HBV core protein phosphorylation in vivo and
their mutants that lacked the kinase activity could still suppress HBV DNA replication. Thus, these findings demonstrate a negative role of
SRPK1 and SRPK2 in the regulation of HBV replication through a mechanism not involving the phosphorylation of the core protein.
D 2005 Elsevier Inc. All rights reserved.Keywords: Hepatitis B virus; HBV core protein phosphorylation; HBV replication; SRPK1; SRPK2Introduction
Hepatitis B virus (HBV) is an enveloped virus with a
DNA genome of 3.2 kb. This virus is a liver-tropic virus.
Upon infection of hepatocytes, the viral DNA genome is
transported into the nucleus where it serves as the template
to direct the synthesis of viral RNAs. One of the viral RNAs
is larger than the genome size and codes for the core protein
and the viral DNA polymerase, which is also a reverse
transcriptase. During the maturation of HBV, the core
protein packages its own mRNA and the viral DNA
polymerase to form the core particle. The viral DNA
polymerase subsequently converts the core protein RNA,
which is also known as the pregenomic RNA (pgRNA), into
the viral DNA genome. The DNA containing core particles
then interact with viral envelope proteins, commonly
referred to as the surface antigens, on the membrane of
the endoplasmic reticulum (ER). The virion is then released0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: jamesou@hsc.usc.edu (J.-H.J. Ou).into the ER lumen and secreted from infected cells (for
reviews, see Ganem and Schneider, 2001; Yen, 2001).
In addition to the viral genome and the DNA polymerase,
the HBV core particle also contains a kinase activity. This
kinase activity can phosphorylate the core protein that forms
the core particle (Albin and Robinson, 1980; Gerlich et al.,
1982). The core protein is hyperphosphorylated in cells
whether it is expressed by itself or from the HBV genome
(Roossinck and Siddiqui, 1987; Yeh and Ou, 1991). Three
serine residues, serine-157, serine-164 and serine-172, have
previously been identified as the major phosphorylation sites
in the core protein sequence (Liao and Ou, 1995). These
serine residues are located in the carboxy-terminal arginine-
rich sequence. The conversion of these three serine residues
to glutamic acid or aspartic acid to mimic phosphoserine did
not prevent the core protein from packaging the HBV
pgRNA. However, it suppresses the viral genomic DNA
replication (Gazina et al., 2000; Kock et al., 2004; Lan et al.,
1999). The conversion of these serine residues to alanine to
mimic nonphosphorylated serine suppresses the packaging
of the pgRNA. Therefore, it has been suggested that the05) 150 – 158
Fig. 1. Suppression of HBV DNA replication by SRPK1 and SRPK2. (A)
Southern blot analysis. Huh7 cells were co-transfected with the HBV
genomic dimer and a control vector (lane 2) or a plasmid that expresses
SRPK1 (lane 3) or SRPK2 (lane 4). A plate of cells was also transfected
with pUC19 and the control vector to serve as a negative control (lane 1).
Cells were lysed 48 h after transfection and treated with DNaseI and
micrococcal nuclease. The HBV DNA packaged in the core particles was
then isolated by proteinase K digestion followed by phenol extraction. The
linearized HBV DNA genome was shown in lane M to serve as a marker.
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for viral pgRNA packaging and DNA replication (Lan et al.,
1999). Daub et al. (2002) identified two additional serine
residues, serine-178 and serine-180, as the phosphorylation
sites in the core protein sequence.
The nature of the endogenous kinase activity associated
with the core particle is controversial. It has been suggested
to be protein kinase C (PKC) (Kann and Gerlich, 1994) and
a 46 kDa protein kinase associated with ribosomes (Kau and
Ting, 1998). These two kinases as well as the cdc2 kinase
can phosphorylate the core protein in vitro (Yeh et al.,
1993). In an attempt to identify the cellular kinase that may
be responsible for the phosphorylation of the HBV core
protein, Daub et al. (2002) fused the core protein sequence
to the glutathione-S-transferase (GST) and used this fusion
protein to isolate cellular proteins that might bind to the core
protein. They identified SRPK1 and SRPK2 as such
proteins. SRPK1 and SRPK2 are approximately 95 kDa
and 115 kDa in size, respectively. These two kinases can
phosphorylate serine/arginine-rich domain (SR-domain)-
containing proteins to affect their biological functions (Gui
et al., 1994a, 1994b; Wang et al., 1998). SR-domain
proteins are RNA binding proteins involved in the formation
of spliceasomes (Zahler et al., 1992). These two kinases can
also phosphorylate the core protein in vitro. Daub et al.
(2002) suggest that these two kinases are most likely the
cellular kinases that mediate the core protein phosphoryla-
tion during HBV infection. In this report, we have tested the
possible effects of SRPK1 and SRPK2 on HBV replication.
Our results indicate that both SRPK1 and SRPK2 could
suppress HBV DNA replication by inhibiting the packaging
of the HBV pregenomic RNAwithout significantly affecting
the formation of viral core particles. Further studies indicate
that this suppressive effect of SRPK1 and SRPK2 on HBV
replication is independent of their kinase activities.
The arrow denotes the 3.2 kb HBV DNA band. The relative DNA levels
were measured using SigmaScan Pro 5. The numbers shown represent the
average of at least three independent experiments. (B) Northern blot
analysis. Huh7 cells were co-transfected with the HBV genomic dimer and
a control vector (lane 1) or an expression vector that expresses SRPK1 (lane
2) or SRPK2 (lane 3). A plasmid that expresses the human growth hormone
(hGH) was also used for co-transfection to monitor the transfection
efficiency. C, S and hGH mark the locations of the C gene transcripts, the S
gene transcripts and the hGH RNA.Results
Suppression of HBV DNA replication by SRPK1 and SRPK2
To investigate the possible effect of SRPK1 and SRPK2
on the replication of HBV, we performed the co-transfection
experiment. The HBV genomic dimer was co-transfected
with the Flag-tagged SRPK1 or SRPK2 expression plasmid
into Huh7 hepatoma cells. Forty-eight hours after trans-
fection, cells were lysed and treated with DNaseI and
micrococcal nuclease to remove the transfected HBV DNA.
The replicated HBV DNA was then released from the core
particles by proteinase K digestion and analyzed by South-
ern blot. As shown in Fig. 1A, the co-expression with
SRPK1 and SRPK2 led to the reduction of the HBV DNA
level by approximately two-fold and eight-fold, respec-
tively. The suppressive effect of SRPK2 was reproducibly
more prominent than SRPK1 in different experiments (also
see below). To investigate how SRPK1 and SRPK2 mighthave suppressed HBV DNA replication, we performed the
Northern blot experiment to analyze HBV RNAs. As shown
in Fig. 1B, the co-expression with SRPK1 and SRPK2 did
not significantly affect the HBV RNA levels, indicating that
the effect of SRPK1 and SRPK2 on the replication of HBV
was most likely a post-transcriptional event.
Suppression of pgRNA packaging by SRPK1 and SRPK2
To further investigate how SRPK1 and SRPK2 may
suppress HBV DNA replication, we had studied their effects
on the encapsidation of the HBV pgRNA. The HBV core
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pgRNA packaged in the core particles were extracted and
quantified by the primer-extension analysis. Interestingly, as
shown in Fig. 2, the co-expression of Flag-tagged SRPK1
and SRPK2 reduced the amount of the pgRNA packaged in
the core particles by approximately two-fold and four-fold,
respectively. As a control, we had also quantified the
pgRNA level in the total cell lysates. As shown in the same
figure, SRPK1 and SRPK2 did not affect the overall
expression level of the pgRNA and its related precore
protein RNA in Huh7 cells (Fig. 2). This result indicated
that the effect of SRPK1 and SRPK2 on HBV replication
most likely occurred at the encapsidation step of the
pgRNA, which in turn led to the reduction of the HBV
DNA level in the core particles.
Suppression of pgRNA packaging but not core particle
formation by SRPK2
To further investigate how SRPK affected the encapsi-
dation of the HBV pgRNA, we also preformed the isopycnic
centrifugation to analyze the HBV core particles. To
simplify our experiments, we decided to focus our studies
on SRPK2, which had a higher suppressive effect on HBV
replication. Huh7 cells were co-transfected with the HBV
genomic DNA and the SRPK2 expression plasmid or itsFig. 2. Primer-extension analysis for the HBV pgRNA. Huh7 cells co-
transfected with the HBV genome and a control vector (lanes 2 and 6) or a
plasmid that expresses SRPK1 (lanes 3 and 7) or SRPK2 (lanes 4 and 8)
were lysed for the isolation of the pgRNA packaged in the core particles
(lanes 1–4) or the total cellular RNA (lanes 5–8). Lanes 1 and 5 are the
cells that were transfected by pUC19 and the control expression vector. The
plasmid that expresses hGH was also used for co-transfection to monitor the
transfection efficiency. Details for the isolation of the viral RNA and the
primer-extension are described in Materials and methods. Precore, core and
hGH indicate the locations of the precore RNA, the core RNA and the hGH
RNA. The numbers shown at the bottom of the gel represent the relative
core RNA (pgRNA) levels. The core RNA signals were measured using
SigmaScan Pro 5. The results represent the average of at least three
independent experiments.control vector. Cells were lysed 48 h after transfection and
analyzed on a density gradient. The density gradient was
fractionated, and the core particle peaks were analyzed by
ELISA. As shown in Fig. 3, in the absence of SRPK2, two
major core particle peaks with densities of 1.35 g/cm3 (Peak
I) and 1.30 g/cm3 (Peak II) were identified. When these two
peaks were analyzed by electron microscopy, they were
found to contain core particles with a similar size and
morphology (Fig. 3, insets). However, when individual
fractions of the gradient were analyzed for HBV DNA by
Southern blot, only the high-density peak fraction was
found to contain the HBV DNA (Fig. 3, bottom panels).
In the presence of SRPK2, the high-density DNA-
containing core particle peak was greatly diminished (Fig.
3). This result is consistent with the results shown in Figs. 1
and 2, which indicated that SRPK2 could suppress the
encapsidation of the HBV pgRNA and hence the subsequent
viral DNA replication. Interestingly, SRPK2 had no
apparent effect on the low-density core particle peak,
indicating that SRPK2 did not affect the formation of the
core particles.
Suppression of HBV replication by SRPK1 and SRPK2 via a
mechanism independent of core protein phosphorylation
As SRPK1 and SRPK2 have been suggested to be the
major kinases that phosphorylate the core protein during
HBV replication, we decided to investigate whether these
two kinases suppressed the encapsidation of the HBV
pgRNA by enhancing the phosphorylation of the core
protein. Huh7 cells were co-transfected with the HBV
genome and a control vector or a plasmid that expressed
Flag-tagged SRPK1 or SRPK2. The cells were then split
into two plates a day after transfection. One of the plates
was labeled with 32P-orthophosphate followed by immu-
noprecipitation with the anti-core antibody, and the other
plate was lysed and used for the Western blot analysis
using the same antibody. As shown in Fig. 4A, the co-
expression of SRPK1 or SRPK2 with the HBV genome
did not significantly affect the phosphorylation or the
expression level of the core protein (Fig. 4A). Similar
results were obtained when the HBV core protein was
expressed by itself in the absence of other HBV gene
products (Fig. 4B). These results raised the possibility that
SRPK1 and SRPK2 did not suppress the encapsidation of
the HBV pgRNA by enhancing the phosphorylation of the
core protein.
To further test whether the kinase activities of SRPK1
and SRPK2 are important for the suppression of HBV
replication, we used the kinase-deficient forms of SRPK1
(SRPK1M) and SRPK2 (SRPK2M) for our studies. We
first tested the kinase activities of SRPK1M and SRPK2M
to ensure that they indeed lacked the kinase activity. Huh7
cells were transfected with a control vector, the expression
plasmid for the Flag-tagged SRPK1 or SRPK2 or the
expression plasmid for the Flag-tagged SRPK1M or
Fig. 3. Density gradient analysis of the HBV core particles. Huh7 cells transfected with the HBV genome with a control vector (solid line) or a plasmid that
expresses SRPK2 (dashed line) were lysed and centrifuged on a 20–50% CsCl density gradient. The gradient was fractionated from the bottom and analyzed
by ELISA (Materials and methods). The high-density (1.35 g/cm3) and the low-density (1.30 g/cm3) core particle peaks are indicated by I and II, respectively.
An aliquot of fractions 3–17 was used for the isolation of the HBV DNA, which was then analyzed by Southern blot (bottom panels). The asterisk marks
Fraction #6, which is the peak fraction of the high-density core particle. The core particle peak fractions were also negatively stained for electron microscopy
for the analysis of the core particles (insets).
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SRPK proteins were immunoprecipitated from the cell
lysates using the anti-Flag antibody. The kinase activities of
various SRPK proteins were then assayed using a peptide
substrate and g-32P-ATP. As shown in Fig. 5A, both Flag-
tagged SRPK1 and SRPK2 had high kinase activities,
whereas Flag-tagged SRPK1M and SRPK2M displayed
low kinase activities similar to those of the background
controls. To examine whether SRPK2M retains the ability
to bind to the core protein, we had performed the co-
immunoprecipitation experiment. As shown in Fig. 5B,
SRPK2 or SRPK2M expressed in Huh7 cells could be
immunoprecipitated by the anti-core antibody in the
presence, but not in the absence, of the core protein. Note
that the expression levels of SRPK2 and SRPK2M in Huh7
cells were similar prior to immunoprecipitation, indicating
that the lack of kinase activity of SRPK2M observed in
Fig. 5A was not due to its instability. We were not able to
detect the binding of SRPK1 or SRPK1M to the core
protein in the same co-immunoprecipitation experiment
(data not shown). This is consistent with the previous
report, which indicated that SRPK1 had a significantly
lower affinity than SRPK2 to the core protein (Daub et al.,
2002). Nevertheless, the expression levels of SRPK1 and
SRPK1M in Huh7 cells prior to immunoprecipitation were
the same, again indicating that the loss of the kinase
activity did not affect the expression level of SRPK1M
(data not shown).Next, we examined the effect of SRPK1M and SRPK2M
on the replication of HBV DNA. The HBV DNA genome
was co-transfected with the expression plasmid for SRPK1,
SRPK1M, SRPK2 or SRPK2M into Huh7 cells. As shown
in Fig. 5C, the ability of SRPK1M and SRPK2M to
suppress HBV DNA replication was only slightly affected
when compared with their respective wild-type proteins.
Thus, these results demonstrated that SRPK1 and SRPK2
could suppress HBV replication via a kinase-independent
pathway.Discussion
SRPK1 and SRPK2 are highly specific kinases for the
SR-domain containing proteins. By conducting the GST-
pulling down experiment followed by mass spectrometry,
Daub et al. (2002) found that SRPK1 and SRPK2 could
bind to and phosphorylate the core protein in vitro. In their
co-expression experiment in Huh7 cells, they found that
SRPK2 could be co-immunoprecipitated with the core
protein, indicating that SRPK2 could also bind to the core
protein in Huh7 cells. In this report, we have investigated
how the interaction between the core protein and SRPK1/2
may affect HBV replication. Our results indicated that both
SRPK1 and SRPK2 could suppress HBV DNA replication,
with the latter having a greater suppressive effect (Fig. 1A).
Neither SRPK1 nor SRPK2 affected the transcription of
Fig. 4. Effects of SRPK kinases on the phosphorylation of the HBV core
protein. (A) Phosphorylation analysis of the core protein expressed from the
HBV DNA genome. Huh7 cells co-transfected with the HBV genome and a
control vector (lane 2) or a plasmid that expresses SRPK1 (lane 3) or
SRPK2 (lane 4) were split into two plates the second day. One plate of cells
was labeled with 32P-orthophosphate on the third day followed by
immunoprecipitation using the anti-core antibody, and the other plate was
lysed and used for the Western blot (WB) analysis. Lane 1 is the negative
control (Cont.) sample. It was derived from cells transfected with pUC19
and the control expression vector. The arrow marks the locations of the core
protein. The arrowhead denotes the precore protein, which is also a
phosphoprotein (Ou et al., 1989; Yeh and Ou, 1991). The asterisk marks the
location of a background band, which served as a loading control. In the
lower WB panel, cells transfected with a plasmid expressing only the core
protein were also shown to the left to serve as a marker to identify the core
protein band. The additional protein bands in the lower panel are the
precore protein derivatives that cross-reacted with the anti-core antibody
(data not shown; Ou et al., 1989). (B) Phosphorylation analysis of the core
protein expressed from pCMV-core, a plasmid that expressed the HBV core
protein only. Huh7 cells were transfected with pUC19 and a control vector
(lane 1), pCMV-core and the control vector (lane 2), pCMV-core and the
SRPK1 expression plasmid (lane 3) or pCMV-core and the SRPK2
expression plasmid.
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two kinases could suppress the encapsidation of the HBV
pgRNA (Fig. 2). Thus, SRPK1 and SRPK2 apparently
suppressed HBV DNA replication by suppressing the
encapsidation of the pgRNA.
To further investigate how SRPKs may suppress HBV
replication, we had also conducted the density gradient
analysis. In our studies on SRPK2, we found that this
kinase could reduce the level of only the high-density
DNA containing core particles but not the low-density core
particles devoid of viral DNA (Fig. 3). This result indicates
that, although SRPK2 affects the encapsidation of the
pgRNA, it does not significantly affect the core particle
formation. Previous studies indicated that SRPK1 and
SRPK2 could physically bind to the carboxy terminus ofthe core protein, with the former having a lower binding
affinity (Daub et al., 2002). As the carboxy terminus of the
core protein is important for the pgRNA packaging, it is
likely that SRPK1 and SRPK2 suppress HBV replication
by interfering with the interaction between the core protein
and the pgRNA and/or the viral DNA polymerase. In this
case, the lower suppressive activity of SRPK1 may be due
to its lower binding affinity to the core protein. Our
observation that the kinase-deficient mutant SRPK2M
could bind to the core protein and suppress HBV
replication with an efficiency similar to that of SRPK2 is
also consistent with this hypothesis (Fig. 5B). The lack of
effect of SRPK2 on the formation of the core particle may
also be explained as the carboxy terminus of the core
protein is not essential for the formation of the core
particle (Kock et al., 2004).
As SRPK1 and SRPK2 can phosphorylate the core
protein in vitro, we have also investigated whether these
two kinases suppressed HBV replication via the phosphor-
ylation of the core protein. As shown in Fig. 4, the co-
expression of these two kinases did not increase the
phosphorylation level of the core protein whether the core
protein was expressed from the HBV genome or by itself
using a heterologous promoter. This result raised the
possibility that SRPK1 and SRPK2 did not suppress
HBV replication by enhancing the phosphorylation of the
core protein. This possibility is further supported by our
studies using the kinase-deficient mutants. In our studies,
we found that abolishing the kinase activities of SRPK1
and SRPK2 only slightly reduced their suppressive
activities on the replication of HBV (Fig. 5C). Thus, these
results together provide a compelling argument that
SRPK1 and SRPK2 can suppress HBV replication via a
phosphorylation-independent pathway. We cannot rule out
the possibility that a kinase-dependent pathway may also
be involved as the suppressive activities of SRPK1M and
SRPK2M on HBV replication were slightly reduced.
SRPK1 and SRPK2 have been suggested to be the
major cellular kinases involved in the phosphorylation of
the core protein during HBV replication (Daub et al.,
2002). In our studies, we were not able to observe a
change in the phosphorylation level of the core protein
whether the expression levels of these two kinases were
increased by over-expression (Fig. 4) or decreased by the
siRNA knockdown experiments (data not shown). One
possible explanation to these results is that a very small
amount of these two kinases was sufficient to fully
phosphorylate the core protein. Hence, the increase or
the decrease of their expression levels had no apparent
effect on the phosphorylation of the core protein. Alter-
natively, it is also possible that these two kinases, which
can bind to the core protein, are not the major enzymes
involved in the phosphorylation of the core protein during
HBV replication. Note that, if these two enzymes are
indeed the kinase found associated with the core particles
in the HBV virions (Albin and Robinson, 1980; Gerlich et
Fig. 5. Effects of the SRPK kinase-negative mutants on HBV DNA replication. (A) Analysis of the kinase activities of various SRPK proteins. Huh7 cells
transfected by the control vector pRc/CMVor the expression plasmid for various Flag-tagged SRPK proteins were lysed 48 h after transfection. Cell lysates
were immunoprecipitated with the anti-Flag antibody. The immunoprecipitates were then incubated with the SRPK substrate peptide for the analysis of the
SRPK kinase activities. (B) Co-immunoprecipitation of SRPK2 and SRPK2M with the HBV core protein. Huh7 cells were co-transfected with control vectors,
the HBV core protein expression plasmid, the SRPK2 plasmid and the SRPK2M plasmid as indicated under the gel. Forty-eight hours after transfection, cells
were lysed. An aliquot of the cell lysates was used directly for Western blot using the anti-SRPK2 antibody (BD Transduction Lab.; lower panel). The rest of
the cell lysates were immunoprecipitated using the rabbit anti-core antibody prior to Western blot analysis using the anti-SRPK2 antibody (upper panel). As
shown in the figure, both SRPK2 and SRPK2M could be immunoprecipitated by the anti-core antibody only in the presence but not in the absence of the core
protein. (C) Effects on HBV DNA replication. Huh7 cells were co-transfected with the HBV genome and the control vector (lane 1) or the expression plasmid
for SRPK1 (lane 2), the SRPK1 mutant (SRPK1M) (lane 3), SRPK2 (lane 4) or the SRPK2 mutant (SRPK2M) (lane 5). The isolation of the HBV DNA and the
subsequent Southern blot procedures were described in Materials and methods. The quantification of the relative DNA levels was determined by using
SigmaScan Pro 5. The numbers shown represent the average of at least three independent experiments.
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kinases at the expense of its replication efficiency. Their
packaging may be required for the proper initiation of
HBV replication in the next infection cycle, such as
facilitating the nuclear transport of the core particles as
what has been proposed (Kann and Gerlich, 1994; Rabe et
al., 2003).
In conclusion, in this report, we demonstrated that
SRPK1 and SRPK2 could suppress HBV DNA replication
via a pathway independent of their kinase activities. This
suppressive effect of SRPK1 and SRPK2 affects theencapsidation of the pgRNA but not the formation of the
core particle. Our studies thus implicate a negative role of
these two kinases in the replication of HBV.Materials and methods
DNA plasmids
The plasmid pWTD contains a head-to-tail dimer of the
HBV (adw2) genome joined at the unique EcoRI site. This
Y. Zheng et al. / Virology 342 (2005) 150–158156plasmid has been described before (Zheng et al., 2004).
pFlag-SRPK1 and pFlag-SRPK2 express human SRPK1
and SRPK2, respectively, using the immediate early pro-
moter of cytomegalovirus (CMV). In both plasmids, the
SRPK sequences were tagged with a Flag epitope at the N-
terminus (Wang et al., 1998). pFlag-SRPK1M and pFlag-
SRPK2M are the two kinase mutants which contain a lysine
to methionine mutation in the ATP binding sites. The
mutation is located at amino acid (aa.) 109 of the SRPK1
sequence and aa. 110 of the SRPK2 sequence. pCMV-core
is a plasmid that expresses only the HBV core protein using
the CMV promoter (Yeh and Ou, 1991).
DNA transfection and Southern blot analysis of replicated
HBV DNA
Huh7 cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) containing 10% fetal bovine
serum. Cells in a 60-mm dish were transfected by a total
amount of 10 Ag DNA plasmids using the calcium
phosphate precipitation method when they were about
80% confluent. Cells were rinsed twice with phosphate-
buffered saline (PBS) 48 h after transfection and lysed in
Tris-buffered saline (TBS; 10 mM Tris–HCl, pH 7, 150
mM NaCl) containing 0.5% Nonidet P-40 (NP40) in a total
volume of 500 Al. The nuclear pellet was removed by a brief
centrifuge at 15,000  g in a microfuge. The cytoplasmic
supernatant was then incubated with 16 units of micrococcal
nuclease (Amersham Pharmacia Biotech Inc.) and 5 Ag of
DNaseI in the presence of 4 mM CaCl2 and 4 mM MgCl2 at
37 -C for 1 h. This nuclease reaction, which removed the
input DNA plasmid, was stopped by the addition of 40 Al
0.5 M EDTA. The replicated HBV DNA in the core
particles was then isolated by proteinase K digestion
followed by phenol extraction using our previous proce-
dures (Zheng et al., 2003). The HBV DNA was subse-
quently analyzed by Southern blot using a 32P-labeled HBV
DNA probe.
Primer-extension analysis for the HBV pregenomic RNA
Cells transfected with the DNA plasmids were rinsed
with PBS, lysed in TBS containing 0.5% NP40 and treated
with micrococcal nuclease and DNaseI as described above.
The core particles in the cytoplasmic lysates were pelleted
at 50,000 rpm in a SW55 rotor for 1 h. The pregenomic
RNA packaged in the core particles was then extracted with
Trizol reagent (Invitrogen) following the manufacturer’s
protocol. The primer-extension analysis was conducted to
quantify the amount of the pregenomic RNA packaged in
the core particles using our previous procedures (Zheng et
al., 2004). A 32P-labeled oligonucleotide containing the
antisense sequence (nucleotide 2052–2025) in the core
protein coding region was used as the primer (Zheng et al.,
2004). For the isolation of the total cellular RNA, cells
were rinsed twice with PBS followed by immediateextraction with Trizol Reagent. A total of 10 Ag total
cellular RNA was also used for the primer-extension
experiment to serve as a control.
Isopycnic centrifugation and enzyme-linked immunosorbent
assay (ELISA)
A total of thirty million Huh7 cells that had been
transfected with the DNA plasmids were lysed in 1.5 ml
TBS containing 0.5% NP40 and 1 mM PMSF. The nuclei
were removed by a brief centrifugation at 15,000  g in a
microcentrifuge. The supernatant was then loaded on a
20–50% CsCl density gradient and centrifuged at 36,000
rpm for 16 h using a SW40 rotor. The gradient was
fractionated from the bottom of the tube, and 0.5-ml
fractions were collected. The Bethyl ELISA kit (Bethyl
Laboratories) was used to analyze the HBV core particles
in the gradient. Briefly, each well of the ELISA plate was
coated overnight at 4 -C with 100 Al rabbit polyclonal
anti-core antibody (Ou et al., 1990) that had been diluted
1:100 in the Bethyl coating buffer. After the removal of the
antibody, the wells were washed with the washing buffer
and then blocked with 200 Al blocking buffer at the room
temperature for 1 h followed by further washing. 50 Al of
the samples from each gradient fraction was then mixed
with 150 Al Bethyl sample dilution buffer and then added
into each well. After the incubation at the room temper-
ature for 1 h, the wells were washed and then incubated
with the mouse monoclonal anti-HBV core antibody
(Abcam; 1:1000 dilution) at the room temperature for
another hour. After further washing, the wells were
incubated with the horseradish-peroxidase-conjugated goat
anti-mouse antibody (1:3000 dilution). The Bethyl TMB
color reaction substrates were then added, and the color
reaction was stopped by the addition of an equal volume
of 2 N H2SO4. The absorbance was measured at 450 nm
using an ELISA reader.
Negative staining of the core particles
Peak fractions of HBV core particles were concentrated
using the Microcon (10 kDa molecular weight cutoff)
ultrafiltration columns (Millipore). Samples were then
stained with 2% uranyl acetate and analyzed with a Zeiss
10 transmission electron microscope.
Phosphorylation analysis of the HBV core protein
Huh7 cells in a 10-cm petri dish were transfected with
the DNA plasmid and then split into two 60-mm dishes on
the second day. One of the plates was used for the 32P-
labeling experiment, and the other plate was used for the
Western blot analysis to monitor the expression level of the
core protein. Forty-eight hours after transfection, cells in
one of the 60-mm dishes were starved in the phosphate-
free medium (Invitrogen) for 1 h and labeled with 0.5 mCi
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the RIPA solution (Li et al., 2004). Chromosomal DNA
were sheared with a 26-gauge needle and removed by two
centrifugations in a microcentrifuge. The supernatant was
then immunoprecipitated with the polyclonal rabbit anti-
core antibody (Ou et al., 1990). For Western blot, cells in
the other 60-mm dish were rinsed with PBS, scraped off
the plate in TBS containing 0.5% NP40 and sonicated.
Cell lysates were then subjected to the Western blot
analysis using the rabbit anti-core antibody (Ou et al.,
1990).
Analysis of the kinase activities of SRPKs and their mutants
Cells transfected with DNA plasmids were rinsed and
collected in 1.5 ml PBS 48 h after transfection. After a
brief centrifugation at 4000 rpm in a microfuge, cell
pellets were sonicated in 300 Al TBS containing 0.5%
NP40 in the presence of the protease inhibitor cocktail
(Roche). Cell lysates were then incubated with 1 Al mouse
monoclonal anti-Flag antibody (Stratagene) at 4 -C over-
night. The immune complex was precipitated using
Gamma-bind (Amersham Biosciences), washed three times
in TBS containing 0.5% NP40 and finally resuspended in
20 Al 2 kinase buffer (100 mM HEPES, pH 7.0, 200
mM NaCl and 20 mM MgCl2). The kinase reaction was
then carried out by incubating 5 Al of the immunopreci-
pitates with 1 ACi g-32P-ATP (3000 Ci/mmol), 50 AM
ATP and 10 Ag SRPKtide (Upstate) at 37 -C for 30 min.
Five-microliter reaction mixture from each reaction was
spotted on a piece of 1 cm2 3MM paper and air-dried. The
3MM paper was then washed at 4 -C once with 20%
trichloroacetic acid (TCA) for 30 min, twice with 5%
TCA for 10 min and then once with methanol for 10 min.
The kinase activities were then determined by scintillation
counting.
Co-immunoprecipitation experiments
Transfected cells in 60-mm dishes were collected and
lysed using the same procedures as described above for the
in vitro kinase assay. The rabbit anti-core antibody was used
for the immunoprecipitation, which was carried out in TBS
containing 0.5% NP40. The immunoprecipitates were
Western-blotted using the mouse monoclonal anti-SRPK2
antibody (BD Transduction Lab).Acknowledgments
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